Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
No abstract is available for this record.
Bibliographic context
- Date
- 2026-01-19
- Source
- OpenAlex
- PubMed
- Unavailable
Authors
Martina ColognesiDaniela GabbiaAnna SignorMiles SarillLucia CentofantiAndrea RinaldiLuciano CascioneSara NunziataMarco BanzatoAndrea MattareiGiovanna FinziSonia SondaDiana PendinIlaria ZanottoStefano ComaiGianfranco PasutAbdullah AlajatiMiriam SaponaroLoredana BucciarelliMaria Elena LunatiAndrea Alimontiet al.
Watch author
Topics and keywords
psilocybin PharmacologyMechanism of ActionReceptor PharmacologyToxicity Other EndocrinologyInsulin resistanceInternal medicineMedicineType 2 diabetesType 2 Diabetes MellitusInsulinPharmacologySerotoninLeptinPsilocybinMetabolic syndromeCarbohydrate metabolismSkeletal muscleDiabetes mellitusInsulin receptorReceptorGlucose uptakeGlucagon-like peptide-1Tryptamine
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
No close related records were found yet.